ストックスクリーナーアプリを入手
21.93
1.20%
0.26
アフターアワーズ：
21.93
前日終値:
$21.67
開ける：
$21.935
24時間の取引高:
850.38K
Relative Volume:
0.99
時価総額：
$3.16B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-7.6947
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
+14.82%
1か月 パフォーマンス:
-5.56%
6か月 パフォーマンス:
-4.69%
1年 パフォーマンス:
+28.10%
1日の値動き範囲:
$21.47
$22.27
1週間の範囲:
$18.52
$22.37
52週間の値動き範囲:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8548
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
21.93 | 3.16B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in December - MarketBeat
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
JPMorgan Chase & Co. Purchases 14,324 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Denali Therapeutics sees cash runway into 2028 - MSN
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
Denali Therapeutics (NASDAQ:DNLI) Stock Price Up 9.8%Still a Buy? - MarketBeat
Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair - MarketBeat
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints - MSN
Denali Therapeutics Announces Key Anticipated 2025 - GlobeNewswire
Denali's Tividenofusp Alfa Earns FDA Breakthrough Status for Hunter Syndrome, BLA Filing Set for 2025 - StockTitan
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock By Investing.com - Investing.com Nigeria
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More - MSN
Denali Therapeutics director Steve Krognes sells $69,484 in stock By Investing.com - Investing.com Australia
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock By Investing.com - Investing.com South Africa
HC Wainwright Has Positive Forecast for DNLI FY2026 Earnings - MarketBeat
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com South Africa
Denali therapeutics’ CFO Alexander Schuth sells shares worth $308,290 By Investing.com - Investing.com Nigeria
Denali therapeutics' CFO Alexander Schuth sells shares worth $308,290 - Investing.com India
Denali Therapeutics CEO Ryan Watts sells $750,955 in stock - Investing.com India
Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares - MarketBeat
Ryan J. Watts Sells 29,266 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock - MarketBeat
Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,339 Shares of Stock - MarketBeat
Denali Therapeutics' chief medical officer Carole Ho sells $308,290 in stock - Investing.com
Denali Therapeutics director Steve Krognes sells $69,484 in stock - Investing.com
Denali Therapeutics stock maintains buy rating on FDA decision By Investing.com - Investing.com Canada
Denali Therapeutics (NASDAQ:DNLI) Trading Up 3.1%Here's What Happened - MarketBeat
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - BioPharma Dive
Denali Therapeutics stock maintains buy rating on FDA decision - Investing.com
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases - BioSpace
Research Analysts Offer Predictions for DNLI FY2028 Earnings - MarketBeat
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Marketscreener.com
Denali receives FDA breakthrough status for Hunter syndrome drug - Investing.com India
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy - GlobeNewswire
Denali Therapeutics (NASDAQ:DNLI) Raised to Strong-Buy at Baird R W - MarketBeat
Denali's Hunter Syndrome Drug Gets FDA Breakthrough Status, Accelerating Path to Approval - StockTitan
Denali Therapeutics price target lowered to $32 from $35 at BTIG - Yahoo Finance
Baird starts Denali Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment - Yahoo! Voices
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):